Skip to main content
Go to homepage

Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)

Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA

Description:

For complete information, please visit the study on clinicaltrials.gov

Interested in participating?
We are currently recruiting
Study Sponsor:

Sanofi / Regeneron Pharmaceuticals

Full IRB Study Title:
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase
IRB Study ID:
160901